Review
Jul 2026
A patent review of mutant-selective PI3Kα inhibitors for the treatment of different cancers (2021 - 2025).
This review evaluates patents of PI3Kα mutant-selective inhibitors disclosed between 2021 and 2025 and examines the binding modes across two distinct allosteric domains: an H1047R-specific pocket (exemplified by Eli Lilly's inhibitors) and a pan-mutant cryptic site (engaged by RLY-2608 and STX-478).
Haixiang Qi, Jiayang Wen, Heng Xu
· Expert Opinion on Therapeuti... · 0 citations